Age Related Macular Degeneration Clinical Trial
Official title:
Combination Therapy in Neovascular Age-Related Macular Degeneration (AMD): A Three-armed, Randomized, Prospective Clinical Trial of Low Fluence Photodynamic Therapy(rPDT) With Adjunctive Avastin and Triamcinolone Acetonide (Kenalog)(Triple Therapy) Versus rPDT With Adjunctive Avastin (Double Therapy) Versus Monotherapy With Avastin.
Verified date | September 2011 |
Source | Lawson Health Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
The primary purpose of the study is to investigate whether patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration, receiving triple or double therapy compared to monotherapy with Avastin will reduce the intervention rate with equivalent safety and efficacy.
Status | Completed |
Enrollment | 103 |
Est. completion date | April 2009 |
Est. primary completion date | April 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: 1. Choroidal neovascularization (CNV) secondary to age-related macular. All lesion subtypes, based upon IVFA evaluation will be included. 2. CNV under the geometric centre of the foveal avascular zone. 3. Evidence of choroidal neovascular activity as suggested by one of the following: sub-retinal lipid, sub-retinal hemorrhage, and documented loss of 3 lines of vision within the last three months. 4. Greatest linear dimension of the lesion </= 5400 um. 5. Visual acuity of between 20/32 and 20/800 in the study eye - Equivalent to Early Treatment of Diabetic Retinopathy Study (ETDRS) eye chart score of 5 to 75 letters at 2 metres. 6. Willingness and ability to participate and provide written informed consent Exclusion Criteria: 1. Individuals with choroidal neovascularization from causes other than AMD. 2. Individuals physically unable to tolerate intravenous fluorescein angiography or Verteporfin injections. (Specifically, individuals with inadequate venous access or an allergy/sensitivity to fluorescein dye/porphyrins will be excluded.) 3. Any intraocular surgery within 3 months in the study eye. 4. Prior retinal or vitreous surgery including posterior segment vitrectomy or scleral buckling in the study eye. 5. Any significant ocular disease that has compromised or could compromise vision in the study eye and confound analysis of the primary outcome. 6. Individuals with physical or mental disabilities that prevent accurate vision testing. 7. History of treatment of CNV in study eye other than extrafoveal confluent laser photocoagulation. 8. Prior photodynamic therapy for CNV in the study eye. 9. Active hepatitis or clinically significant liver disease 10. Any patient with recent history of new onset cardiac disease or thromboembolic CNS event in the past. 11. Subjects who are in an experimental therapy study or who have received experimental therapy within the last 12 weeks. 12. Subjects who are a poor medical risk because of other systemic diseases or active uncontrolled infections. 13. Women of child-bearing potential who are not on two forms of effective contraception during the trial and for at least 60 days following the last dose of study medications. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | The University of Alberta and Capital Health | Edmonton | Alberta |
Canada | Ivey Eye Institute, St. Joseph's Health Care Centre | London | Ontario |
Canada | Sunnybrook Health Sciences Centre | Toronto | Ontario |
Canada | The University of British Columbia | Vancouver | British Columbia |
Canada | Dr. Stanley G. Shortt | Victoria | British Columbia |
Lead Sponsor | Collaborator |
---|---|
Lawson Health Research Institute | Canadian Retinal Trials Group, QLT Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy. | 1 year | No | |
Secondary | To compare between treatment groups: | 1 year | No | |
Secondary | Whether combination therapy with rPDT + iA and rPDT + iAK in patients with sub-foveal CNVM of all types secondary to ARMD will result in a significant improvement in visual acuity defined as 2 or more lines (10+ letters) on a standardized ETDRS chart c | 1 year | No | |
Secondary | Lesion growth and activity over the study period. | 1 year | No | |
Secondary | Contrast sensitivity. | 1 year | No | |
Secondary | The rate of cataract progression. | 1 year | No | |
Secondary | Central retinal thickness via Optical Coherence Tomography (OCT). | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 | |
Completed |
NCT00358345 -
PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization
|
Phase 4 |